Greek pharma faces new crunch moment
This article was originally published in Scrip
A new draft law is looming in Greece which will have far-reaching implications for the pharmaceutical industry. As the various stakeholders haggle over the 2014 medicines budget – and industry warns that a threatened cut of more than 15% to the outpatient drugs bill could spell catastrophe for public health – the health ministry is preparing a draft law on pricing, reimbursement and other issues relevant to the pharma sector that is expected before the end of the month.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.